Hassan Ahangar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hassan Ahangar has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Sepehr Gohari
School of Medicine, Student Research Center Zanjan University of Medical Science Zanjan Iran
9 shared publicationsTara Reshadmanesh
School of Medicine, Student Research Center Zanjan University of Medical Science Zanjan Iran
9 shared publicationsFaramarz Ismail-Beigi
Department of Medicine, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, USA
5 shared publicationsMohsen Dadashi
Department of Cardiology, School of Medicine, Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran
5 shared publicationsSamin Ghanbari
Department of Cardiology, School of Medicine, Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran
5 shared publicationsShahram Arsang-Jang
Department of Biostatistics, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
5 shared publications
Latest Publications
- Open Access
- 16 January 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (1) , e70354
Assessment of Bendopnea and Its Association With Clinical and Para‐Clinical Findings in Systolic Heart Failure: A Cross‐Sectional Study
Background and Aims: Bendopnea is a symptom found in patients with heart failure (HF) defined as shortness of breath when bending forward. The present study examined the correlation between bendopnea with other cardiac symptoms, echocardiographic findings, and cardiac function parameters. Methods: This was a single‐center prospective cross‐sectional study of patients diagnosed with systolic HF. Medical history, bending tests, laboratory tests, electrocardiography (ECG), echocardiography, and 6‐min walking test (6‐MWT) were evaluated. Patients with reduced ejection fraction were followed to assess the 2‐year outcomes for cardiovascular death and rehospitalization. Results: A total of 80 patients were included in this study, of whom 54 (67.5%) were male. Bendopnea was present in 34 (42.5%) and their mean age was 62.44 years (compared to group without bendopnea, p = 0.869). Symptoms of HF such as dyspnea of exertion (DOE) and orthopnea were significantly related to the presence of bendopnea ( p = 0.001, odds ratio (OR): 6.87, and p = 0.016, OR: 3.18, respectively). The bendopnea‐positive group had a higher New York Heart Association (NYHA) class ( p = 0.005). ECG results showed no significant difference between the two groups. The echocardiographic findings showed that the inferior vena cava (IVC) respiratory collapse was significantly lower in the bendopnea‐positive group ( p = 0.019, OR: 0.339, 95% CI:0.13–0.85). Moreover, they had a substantially lower performance in 6‐MWT (387.39 vs. 325.58 m, p = 0.015). Neither rehospitalization nor death was related to bendopnea after a 2‐year follow‐up ( p = 0.454). Conclusion: Bendopnea was associated with several signs and symptoms of HF, including orthopnea, DOE, NYHA class, lower IVC collapse, and impaired functional capacity measured via 6‐MWT. However, there was no association between bendopnea and ECG findings, ejection fraction, and NT‐proBNP levels. Further studies with larger sample sizes are needed to assess the associations with long‐term outcomes and confirm our findings.
- 16 January 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (1) , e70354
Open AccessAssessment of Bendopnea and Its Association With Clinical and Para‐Clinical Findings in Systolic Heart Failure: A Cross‐Sectional Study
Background and Aims: Bendopnea is a symptom found in patients with heart failure (HF) defined as shortness of breath when bending forward. The present study examined the correlation between bendopnea with other cardiac symptoms, echocardiographic findings, and cardiac function parameters. Methods: This was a single‐center prospective cross‐sectional study of patients diagnosed with systolic HF. Medical history, bending tests, laboratory tests, electrocardiography (ECG), echocardiography, and 6‐min walking test (6‐MWT) were evaluated. Patients with reduced ejection fraction were followed to assess the 2‐year outcomes for cardiovascular death and rehospitalization. Results: A total of 80 patients were included in this study, of whom 54 (67.5%) were male. Bendopnea was present in 34 (42.5%) and their mean age was 62.44 years (compared to group without bendopnea, p = 0.869). Symptoms of HF such as dyspnea of exertion (DOE) and orthopnea were significantly related to the presence of bendopnea ( p = 0.001, odds ratio (OR): 6.87, and p = 0.016, OR: 3.18, respectively). The bendopnea‐positive group had a higher New York Heart Association (NYHA) class ( p = 0.005). ECG results showed no significant difference between the two groups. The echocardiographic findings showed that the inferior vena cava (IVC) respiratory collapse was significantly lower in the bendopnea‐positive group ( p = 0.019, OR: 0.339, 95% CI:0.13–0.85). Moreover, they had a substantially lower performance in 6‐MWT (387.39 vs. 325.58 m, p = 0.015). Neither rehospitalization nor death was related to bendopnea after a 2‐year follow‐up ( p = 0.454). Conclusion: Bendopnea was associated with several signs and symptoms of HF, including orthopnea, DOE, NYHA class, lower IVC collapse, and impaired functional capacity measured via 6‐MWT. However, there was no association between bendopnea and ECG findings, ejection fraction, and NT‐proBNP levels. Further studies with larger sample sizes are needed to assess the associations with long‐term outcomes and confirm our findings.
- Open Access
- 4 July 2024
- Published by Wiley in Clinical Cardiology
- Vol. 47 (7) , e24315
Circulating Levels of Calprotectin as a Biomarker in Patients With Coronary Artery Disease: A Systematic Review and Meta‐Analysis
Background: Calprotectin, also known as MRP8/14, is generated by immune cells and is altered in several inflammatory diseases. Studies have assessed their levels in patients with coronary artery disease (CAD) and its subtypes (stable CAD and acute coronary syndrome [ACS]). Herein, we aimed to systematically investigate these associations through a systematic review and meta‐analysis.Methods: A systematic search was conducted in four online databases, including PubMed, Scopus, Embase, and the Web of Science. Relevant studies were retrieved, screened, and extracted. Random‐effect meta‐analysis was performed for the calculation of standardized mean difference (SMD) and 95% confidence interval (CI). Blood calprotectin levels were compared between CAD patients and controls, as well as CAD subtypes.Results: A total of 20 studies were included in the systematic review and meta‐analysis, comprising 3300 CAD patients and 1230 controls. Patients with CAD had significantly higher calprotectin levels (SMD 0.81, 95% CI 0.32−1.30, p < 0.01). Similarly, patients with ACS were reported to have higher levels compared to those with stable CAD. However, there was no significant difference in terms of blood calprotectin levels between stable CAD cases and healthy controls. Finally, studies have shown that calprotectin could be used as a diagnostic biomarker of CAD while also predicting major adverse events and mortality in these patients.Conclusion: Based on our findings, calprotectin, as an inflammatory marker, could be used as a possible biomarker for patients with CAD and ACS. These suggest the possibility of pathophysiological pathways for this involvement and warrant further research on these associations as well as their clinical utility.
- 4 July 2024
- Published by Wiley in Clinical Cardiology
- Vol. 47 (7) , e24315
Open AccessCirculating Levels of Calprotectin as a Biomarker in Patients With Coronary Artery Disease: A Systematic Review and Meta‐Analysis
Background: Calprotectin, also known as MRP8/14, is generated by immune cells and is altered in several inflammatory diseases. Studies have assessed their levels in patients with coronary artery disease (CAD) and its subtypes (stable CAD and acute coronary syndrome [ACS]). Herein, we aimed to systematically investigate these associations through a systematic review and meta‐analysis.Methods: A systematic search was conducted in four online databases, including PubMed, Scopus, Embase, and the Web of Science. Relevant studies were retrieved, screened, and extracted. Random‐effect meta‐analysis was performed for the calculation of standardized mean difference (SMD) and 95% confidence interval (CI). Blood calprotectin levels were compared between CAD patients and controls, as well as CAD subtypes.Results: A total of 20 studies were included in the systematic review and meta‐analysis, comprising 3300 CAD patients and 1230 controls. Patients with CAD had significantly higher calprotectin levels (SMD 0.81, 95% CI 0.32−1.30, p < 0.01). Similarly, patients with ACS were reported to have higher levels compared to those with stable CAD. However, there was no significant difference in terms of blood calprotectin levels between stable CAD cases and healthy controls. Finally, studies have shown that calprotectin could be used as a diagnostic biomarker of CAD while also predicting major adverse events and mortality in these patients.Conclusion: Based on our findings, calprotectin, as an inflammatory marker, could be used as a possible biomarker for patients with CAD and ACS. These suggest the possibility of pathophysiological pathways for this involvement and warrant further research on these associations as well as their clinical utility.
- Open Access
- 7 May 2024
- Published by Maad Rayan Publishing Company in Disease and Diagnosis
- Vol. 13 (3) , 130-135
Effects of Opium Use on Early and Long-term Outcomes Following Coronary Artery Bypass Grafting: A Systematic Review
Background: The role of opium use history in complications after coronary artery bypass grafting (CABG) is still unclear. This study aimed to systematically review the effect of opium use history on the outcomes of CABG in patients with coronary heart disease. Methods: The present systematic review followed the guidelines for the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA). Manuscript databases, including PubMed, Web of Science, and Scopus, were deeply searched by two blinded investigators for all studies based on the relevant keywords. Google Scholar, Research Gate, and the Cochrane Library were searched as well. Of the twenty-four studies initially collected by database searching, eight were eligible for the final analysis. Results: The results revealed that opium use history led to an increase in the risk of pulmonary and neurological complications, infections, bleeding volume, and atrial fibrillation in-hospital outcomes. In the evaluation of one-year outcomes after surgery, the findings showed an increase in hospital admissions in opium-consuming patients. In addition, in the examination of long-term outcomes, an increase in the risk of long-term mortality and, as a result, a decrease in the long-term survival of opium-using patients could be predicted following the use of opium; however, opium use did not have a significant effect on the long-term major adverse cardiovascular events of patients. Conclusion: Opium use history is a risk factor for the occurrence of postoperative hospital complications, the need for hospital readmission, and long-term CABG postoperative mortality.
- 7 May 2024
- Published by Maad Rayan Publishing Company in Disease and Diagnosis
- Vol. 13 (3) , 130-135
Open AccessEffects of Opium Use on Early and Long-term Outcomes Following Coronary Artery Bypass Grafting: A Systematic Review
Background: The role of opium use history in complications after coronary artery bypass grafting (CABG) is still unclear. This study aimed to systematically review the effect of opium use history on the outcomes of CABG in patients with coronary heart disease. Methods: The present systematic review followed the guidelines for the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA). Manuscript databases, including PubMed, Web of Science, and Scopus, were deeply searched by two blinded investigators for all studies based on the relevant keywords. Google Scholar, Research Gate, and the Cochrane Library were searched as well. Of the twenty-four studies initially collected by database searching, eight were eligible for the final analysis. Results: The results revealed that opium use history led to an increase in the risk of pulmonary and neurological complications, infections, bleeding volume, and atrial fibrillation in-hospital outcomes. In the evaluation of one-year outcomes after surgery, the findings showed an increase in hospital admissions in opium-consuming patients. In addition, in the examination of long-term outcomes, an increase in the risk of long-term mortality and, as a result, a decrease in the long-term survival of opium-using patients could be predicted following the use of opium; however, opium use did not have a significant effect on the long-term major adverse cardiovascular events of patients. Conclusion: Opium use history is a risk factor for the occurrence of postoperative hospital complications, the need for hospital readmission, and long-term CABG postoperative mortality.
- 7 March 2024
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 23 (1) , 1107-1111
Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trial
Background Sodium glucose co-transporter2 (SGLT2) inhibitors have exhibited cardioprotective properties in diabetes patients. The aim of this study was to investigate the effect of Empagliflozin on changes in echocardiographic parameters. Methods This was a post hoc analysis of the EMPA-CARD trial which was a multicenter, triple-blind randomized controlled trial. Type 2 diabetes mellitus patients with concomitant history of coronary artery disease were randomized on a 1:1 ratio into two groups receiving either 10 mg/day Empagliflozin or placebo. Patients with a history of heart failure (NYHA class 3–4) and ejection fraction (EF) < 40% were excluded. Trans-thoracic echocardiography was performed at baseline and at 26 weeks of intervention. Results A total of 69 (Empagliflozin = 39 and placebo = 30) patients underwent echocardiography. Significant changes were observed for left ventricular ejection fraction [standard error (SE) = 0.76; beta (95% correlation interval (CrI)] = -5.558 (-7.25; -4.18) and left ventricular end-systolic volume (SE = 1.38; beta (95% CrI) = 3.915 (1.2; 0.66). Other echocardiographic parameters relating to right ventricular or atrial function did not change significantly. Conclusion Empagliflozin can have cardioprotective benefits in subjects without HF. Further studies are required to determine the effect of Empagliflozin in non-HF patients. Trial registration The original EMPA-CARD study has been registered in Iranian Registry of Clinical Trials. www.IRCT.ir, Identifier: IRCT20190412043247N2. Registration Date: 6/13/2020. Registration timing: prospective.
- 7 March 2024
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 23 (1) , 1107-1111
Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trial
Background Sodium glucose co-transporter2 (SGLT2) inhibitors have exhibited cardioprotective properties in diabetes patients. The aim of this study was to investigate the effect of Empagliflozin on changes in echocardiographic parameters. Methods This was a post hoc analysis of the EMPA-CARD trial which was a multicenter, triple-blind randomized controlled trial. Type 2 diabetes mellitus patients with concomitant history of coronary artery disease were randomized on a 1:1 ratio into two groups receiving either 10 mg/day Empagliflozin or placebo. Patients with a history of heart failure (NYHA class 3–4) and ejection fraction (EF) < 40% were excluded. Trans-thoracic echocardiography was performed at baseline and at 26 weeks of intervention. Results A total of 69 (Empagliflozin = 39 and placebo = 30) patients underwent echocardiography. Significant changes were observed for left ventricular ejection fraction [standard error (SE) = 0.76; beta (95% correlation interval (CrI)] = -5.558 (-7.25; -4.18) and left ventricular end-systolic volume (SE = 1.38; beta (95% CrI) = 3.915 (1.2; 0.66). Other echocardiographic parameters relating to right ventricular or atrial function did not change significantly. Conclusion Empagliflozin can have cardioprotective benefits in subjects without HF. Further studies are required to determine the effect of Empagliflozin in non-HF patients. Trial registration The original EMPA-CARD study has been registered in Iranian Registry of Clinical Trials. www.IRCT.ir, Identifier: IRCT20190412043247N2. Registration Date: 6/13/2020. Registration timing: prospective.
- 22 September 2023
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 22 (2) , 1723-1730
Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial
Background Empagliflozin is a sodium glucose cotransporter-2 (SGLT2) inhibitor that has been suggested to improve cardiac function and vascular recovery. The risk of coronary artery diseases is much higher in diabetic patients and is associated with greater morbidity and mortality. High-sensitivity cardiac troponin-I (hs-cTnI) is an important prognostic biomarker in cardiac diseases. Therefore, this study aimed to investigate the effect of empagliflozin compared to placebo on changes in hs-cTnI and lipid profile after 26 weeks of treatment. Methods This was an ancillary study in a randomized trial of patients with concomitant type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) (The EMPA-CARD study). Patients who were already on standard anti-diabetic/anti-ischemic medications were randomized to receive either placebo or empagliflozin 10 mg/daily. Serum hs-cTnI and lipid profile were measured at baseline and after 26 weeks. Results Of the 95 randomized patients, hs-cTnI and lipid profile were measured for a total of 77 patients. No significant difference was observed regarding the baseline characteristics between the two arms. Compared to placebo, empagliflozin significantly reduced hs-cTnI after 26 weeks (mean difference (MD) of -13.242, 95%CI: -14.151 to -12.333, p < 0.001). In the empagliflozin group, non-significant reductions in total cholesterol, LDL-C, and triglyceride have resulted; however, there was an increase in HDL-C level (MD = 2.40,95%CI:0.16–4.60, p < 0.04). Conclusion Empagliflozin compared to placebo was superior in reducing circulating hs-cTnI that may indicate improvements in cardiomyocytes function in patients with T2DM and CAD. Moreover, empagliflozin had a modest impact on the serum lipid profile biomarkers. Trial registration The original EMPA-CARD study has been registered in Iranian Registry of Clinical Trials. www.IRCT.ir, Identifier: IRCT20190412043247N2. Registration Date: 6/13/2020. Registration timing: prospective.
- 22 September 2023
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 22 (2) , 1723-1730
Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial
Background Empagliflozin is a sodium glucose cotransporter-2 (SGLT2) inhibitor that has been suggested to improve cardiac function and vascular recovery. The risk of coronary artery diseases is much higher in diabetic patients and is associated with greater morbidity and mortality. High-sensitivity cardiac troponin-I (hs-cTnI) is an important prognostic biomarker in cardiac diseases. Therefore, this study aimed to investigate the effect of empagliflozin compared to placebo on changes in hs-cTnI and lipid profile after 26 weeks of treatment. Methods This was an ancillary study in a randomized trial of patients with concomitant type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) (The EMPA-CARD study). Patients who were already on standard anti-diabetic/anti-ischemic medications were randomized to receive either placebo or empagliflozin 10 mg/daily. Serum hs-cTnI and lipid profile were measured at baseline and after 26 weeks. Results Of the 95 randomized patients, hs-cTnI and lipid profile were measured for a total of 77 patients. No significant difference was observed regarding the baseline characteristics between the two arms. Compared to placebo, empagliflozin significantly reduced hs-cTnI after 26 weeks (mean difference (MD) of -13.242, 95%CI: -14.151 to -12.333, p < 0.001). In the empagliflozin group, non-significant reductions in total cholesterol, LDL-C, and triglyceride have resulted; however, there was an increase in HDL-C level (MD = 2.40,95%CI:0.16–4.60, p < 0.04). Conclusion Empagliflozin compared to placebo was superior in reducing circulating hs-cTnI that may indicate improvements in cardiomyocytes function in patients with T2DM and CAD. Moreover, empagliflozin had a modest impact on the serum lipid profile biomarkers. Trial registration The original EMPA-CARD study has been registered in Iranian Registry of Clinical Trials. www.IRCT.ir, Identifier: IRCT20190412043247N2. Registration Date: 6/13/2020. Registration timing: prospective.
- Open Access
- 1 June 2023
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 31 (146) , 210-220
Assessment of Machine Learning Approaches to Predict in-Hospital Mortality in Patients Underwent Prosthetic Heart Valve Replacement Surgery
Background and Objective: Machine learning and artificial intelligence are useful tools to analyze data with multiple variables. It has been shown that the prediction models obtained by Machine learning have better performance than the conventional statistical methods. This study was aimed to assess the risk factors and determine the best machine ...
- 1 June 2023
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 31 (146) , 210-220
Open AccessAssessment of Machine Learning Approaches to Predict in-Hospital Mortality in Patients Underwent Prosthetic Heart Valve Replacement Surgery
Background and Objective: Machine learning and artificial intelligence are useful tools to analyze data with multiple variables. It has been shown that the prediction models obtained by Machine learning have better performance than the conventional statistical methods. This study was aimed to assess the risk factors and determine the best machine ...
- Open Access
- 16 March 2023
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 15 (1) , 22-29
Effectiveness of "Centaurea behen" root on quality of life in patients with systolic heart failure: A randomized clinical trial
Introduction: The effect of Centaurea behen (Cb) on patients with systolic heart failure is not known academically. This study was conducted to evaluate the effect of Cb on improving the quality of life (QoL) and echocardiographic and biochemical blood parameters in patients with systolic heart failure. Methods: This study was a parallel double-blind, placebo-controlled randomized trial of 60 patients with systolic heart failure, was conducted from May 2018 up to August 2019. Intervention group received 150 mg twice daily Cb capsules for two months + Guideline directed medical therapy (GDMT), and control group received GDMT + placebo capsules for two months. The main aim of the present study were to assess the QoL based on the 6-minute walk test (6MWT) and the Minnesota living with heart failure questionnaire (MLHFQ). Independent T-test, paired T-test, and ANOVA were used for the analysis. Results: At the beginning of the present study there were no significant differences between study groups in terms of QoL and clinical results. After treatment, the average values of QoL based on MLHFQ and 6MWT instruments were significantly improved 15.5 and 36.18, respectively (P<0.05). Conclusion: Based on the MLHFQ, and 6MWT tests, the consumption of Centaurea behen root extract was associated with significant improvement in the quality of life of patients with systolic heart failure.
- 16 March 2023
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 15 (1) , 22-29
Open AccessEffectiveness of "Centaurea behen" root on quality of life in patients with systolic heart failure: A randomized clinical trial
Introduction: The effect of Centaurea behen (Cb) on patients with systolic heart failure is not known academically. This study was conducted to evaluate the effect of Cb on improving the quality of life (QoL) and echocardiographic and biochemical blood parameters in patients with systolic heart failure. Methods: This study was a parallel double-blind, placebo-controlled randomized trial of 60 patients with systolic heart failure, was conducted from May 2018 up to August 2019. Intervention group received 150 mg twice daily Cb capsules for two months + Guideline directed medical therapy (GDMT), and control group received GDMT + placebo capsules for two months. The main aim of the present study were to assess the QoL based on the 6-minute walk test (6MWT) and the Minnesota living with heart failure questionnaire (MLHFQ). Independent T-test, paired T-test, and ANOVA were used for the analysis. Results: At the beginning of the present study there were no significant differences between study groups in terms of QoL and clinical results. After treatment, the average values of QoL based on MLHFQ and 6MWT instruments were significantly improved 15.5 and 36.18, respectively (P<0.05). Conclusion: Based on the MLHFQ, and 6MWT tests, the consumption of Centaurea behen root extract was associated with significant improvement in the quality of life of patients with systolic heart failure.
- Open Access
- 1 March 2023
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 31 (145) , 204-206
Delayed Diagnosis of Shone Syndrome in a Patient Planning for Pregnancy
Shone syndrome is a rare congenital cardiac abnormality; however, many of the cases remain undiagnosed until early and middle adulthood. Different imaging modalities are used to assess the related structural abnormalities. In this case study, we report a 32-year-old woman who was planning her first pregnancy. In light of her childhood heart ...
- 1 March 2023
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 31 (145) , 204-206
Open AccessDelayed Diagnosis of Shone Syndrome in a Patient Planning for Pregnancy
Shone syndrome is a rare congenital cardiac abnormality; however, many of the cases remain undiagnosed until early and middle adulthood. Different imaging modalities are used to assess the related structural abnormalities. In this case study, we report a 32-year-old woman who was planning her first pregnancy. In light of her childhood heart ...
- Open Access
- 30 January 2023
- Published by Springer Nature in Thrombosis Journal
- Vol. 21 (1) , 1-6
Low dose ultra-slow infusion thrombolytic therapy (LDUSITT) as an alternative option in a COVID-19 patient with free-floating right atrial thrombus: a case report and review of literature
The hyper-coagulopathy nature of COVID-19 is a prevalent consequence among patients. Free-floating right atrial thrombi are a relatively rare finding and the optimal therapy is a therapeutic dilemma. We present a 37-year-old woman with acute dyspnea and fatigue. Several ground glass opacities were shown on computed tomography of chest that further proved to be associated with severe COVID-19 disease. A transthoracic echocardiography revealed a mobile right atrial mass with bilateral pulmonary embolism. She was considered high risk for surgical therapy by cardiovascular surgeons. She was then started on anticoagulation therapy for 5 days however the size regression of the thrombus remained unchanged. A regimen of low dose (24 mg) ultra-slow (24 h) intravenous infusion of alteplase, without bolus was initiated. Following the third day of thrombolytic therapy, the control echocardiography demonstrated complete resolution of the thrombus. Prolonged infusion of low dose fibrinolytics can be an alternative treatment to surgery for right heart thrombi.
- 30 January 2023
- Published by Springer Nature in Thrombosis Journal
- Vol. 21 (1) , 1-6
Open AccessLow dose ultra-slow infusion thrombolytic therapy (LDUSITT) as an alternative option in a COVID-19 patient with free-floating right atrial thrombus: a case report and review of literature
The hyper-coagulopathy nature of COVID-19 is a prevalent consequence among patients. Free-floating right atrial thrombi are a relatively rare finding and the optimal therapy is a therapeutic dilemma. We present a 37-year-old woman with acute dyspnea and fatigue. Several ground glass opacities were shown on computed tomography of chest that further proved to be associated with severe COVID-19 disease. A transthoracic echocardiography revealed a mobile right atrial mass with bilateral pulmonary embolism. She was considered high risk for surgical therapy by cardiovascular surgeons. She was then started on anticoagulation therapy for 5 days however the size regression of the thrombus remained unchanged. A regimen of low dose (24 mg) ultra-slow (24 h) intravenous infusion of alteplase, without bolus was initiated. Following the third day of thrombolytic therapy, the control echocardiography demonstrated complete resolution of the thrombus. Prolonged infusion of low dose fibrinolytics can be an alternative treatment to surgery for right heart thrombi.
- Open Access
- 17 November 2022
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 14 (1) , 1-13
The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
Systemic inflammation and oxidative burden in patients with type 2 diabetes mellitus (T2DM) causes deleterious cardiovascular outcomes. We sought to investigate the clinical antioxidative and anti-inflammatory effects of empagliflozin. Platelet function, oxidant and antioxidant biomarkers and pro-inflammatory agents at baseline and at 26 weeks were measured. A total of 95 patients (41.05% male, mean age 62.85 ± 7.91 years, mean HbA1c 7.89 ± 0.96%) with concomitant T2DM and coronary artery disease (CAD) were randomized (1:1) to receive empagliflozin (10 mg/daily) or placebo. Patients treated with empagliflozin had lower levels of interleukin 6 (IL-6) (adjusted difference (adiff): − 1.06 pg/mL, 95% CI − 1.80; − 0.32, P = 0.006), interleukin 1β (IL-1β) and high-sensitive C-reactive protein (Hs-CRP) (adiff: − 4.58 pg/mL and − 2.86 mg/L; P = 0.32 and 0.003, respectively) compared to placebo. There were elevations in super oxidase dismutase (SOD) activity, glutathione (GSHr), and total antioxidant capacity (TAC) with empagliflozin (adiff: 3.7 U/mL, 0.57 muM, and 124.08 mmol/L, 95% CI 1.36; 6.05, 0.19; 0.95, and 47.98; 200.18, P = 0.002, 0.004, and 0.002, respectively). While reactive oxygen species (ROS) improved significantly (adiff: − 342.51, 95% CI − 474.23; − 210.79, P < 0.001), the changes in catalase activity (CAT), malondialdehyde (MDA), or protein carbonyl groups (PCG) were not significant. Moreover, the P-selectin antigen expression on platelet surface was significantly reduced (adiff: − 8.81, 95% CI − 14.87; − 2.75, P = 0.005). Markers of glycemic status (fasting blood glucose, HbA1c, and HOMA-IR (homeostatic model assessment for insulin resistance) significantly improved (P < 0.001). Among patients with T2DM and CAD, 6-month treatment with empagliflozin can mitigate inflammation, platelet activity and oxidative stress and is associated with clinical cardiovascular benefits.Trial Registration Iranian Registry of Clinical Trials. www.IRCT.ir, Identifier: IRCT20190412043247N2. Registration Date: 6/13/2020. Registration timing: prospective
- 17 November 2022
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 14 (1) , 1-13
Open AccessThe effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
Systemic inflammation and oxidative burden in patients with type 2 diabetes mellitus (T2DM) causes deleterious cardiovascular outcomes. We sought to investigate the clinical antioxidative and anti-inflammatory effects of empagliflozin. Platelet function, oxidant and antioxidant biomarkers and pro-inflammatory agents at baseline and at 26 weeks were measured. A total of 95 patients (41.05% male, mean age 62.85 ± 7.91 years, mean HbA1c 7.89 ± 0.96%) with concomitant T2DM and coronary artery disease (CAD) were randomized (1:1) to receive empagliflozin (10 mg/daily) or placebo. Patients treated with empagliflozin had lower levels of interleukin 6 (IL-6) (adjusted difference (adiff): − 1.06 pg/mL, 95% CI − 1.80; − 0.32, P = 0.006), interleukin 1β (IL-1β) and high-sensitive C-reactive protein (Hs-CRP) (adiff: − 4.58 pg/mL and − 2.86 mg/L; P = 0.32 and 0.003, respectively) compared to placebo. There were elevations in super oxidase dismutase (SOD) activity, glutathione (GSHr), and total antioxidant capacity (TAC) with empagliflozin (adiff: 3.7 U/mL, 0.57 muM, and 124.08 mmol/L, 95% CI 1.36; 6.05, 0.19; 0.95, and 47.98; 200.18, P = 0.002, 0.004, and 0.002, respectively). While reactive oxygen species (ROS) improved significantly (adiff: − 342.51, 95% CI − 474.23; − 210.79, P < 0.001), the changes in catalase activity (CAT), malondialdehyde (MDA), or protein carbonyl groups (PCG) were not significant. Moreover, the P-selectin antigen expression on platelet surface was significantly reduced (adiff: − 8.81, 95% CI − 14.87; − 2.75, P = 0.005). Markers of glycemic status (fasting blood glucose, HbA1c, and HOMA-IR (homeostatic model assessment for insulin resistance) significantly improved (P < 0.001). Among patients with T2DM and CAD, 6-month treatment with empagliflozin can mitigate inflammation, platelet activity and oxidative stress and is associated with clinical cardiovascular benefits.Trial Registration Iranian Registry of Clinical Trials. www.IRCT.ir, Identifier: IRCT20190412043247N2. Registration Date: 6/13/2020. Registration timing: prospective